galidesivir
Galidesivir is an antiviral drug, an adenosine analog. It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus. — Wikipedia
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2014 (NCT02319772)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Cellular kinases generate the monophosphate which is incorporated into RNA by RNA polymerase causing premature chain termination.
Active against RNA viruses in nine families.
- RNA-directed RNA polymerase LINHIBITOR
RNA-directed RNA polymerase L inhibitor
Cellular kinases generate the monophosphate which is incorporated into RNA by RNA polymerase causing premature chain termination.
Active against RNA viruses in nine families.
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Cellular kinases generate the monophosphate which is incorporated into RNA by RNA polymerase causing premature chain termination.
Active against RNA viruses in nine families.
- RNA-directed RNA polymerase LINHIBITOR
RNA-directed RNA polymerase L inhibitor
Cellular kinases generate the monophosphate which is incorporated into RNA by RNA polymerase causing premature chain termination.
Active against RNA viruses in nine families.
- Replicase polyprotein 1abINHIBITOR
Replicase polyprotein 1ab inhibitor
Cellular kinases generate the monophosphate which is incorporated into RNA by RNA polymerase causing premature chain termination.
Active against RNA viruses in nine families.
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
SMILES
Nc1ncnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12- Mol. weight
- 265.27 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGalidesivir ↗
- ChEMBLCHEMBL1236524 ↗
Also known as
- 2-(4-amino-5h-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
- bcx4430
- bcx4430
- bcx4430
- galidesivir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03891420 | Phase 1 | Apr 15, 2019 | BioCryst, National Institute of Allergy and Infectious Diseases (NIAID), University of Sao Paulo |
| NCT03800173 | Phase 1 | Dec 10, 2018 | BioCryst, National Institute of Allergy and Infectious Diseases (NIAID), Pharmaceutical Research Associates, Inc. (PRA) |
| NCT02319772 | Phase 1 | Dec 1, 2014 | BioCryst, National Institute of Allergy and Infectious Diseases (NIAID), Quotient |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioCryst | For profit | 3 | 3 | 1 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 0 | 1 | 2014 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2018 |
| Quotient | For profit | 1 | 0 | 1 | 2014 |
| University of Sao Paulo | Academic/Hospital | 1 | 0 | 1 | 2019 |